Skip to main content
Erschienen in: Diabetologia 5/2008

01.05.2008 | Article

LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat

verfasst von: J. L. Figarola, S. Loera, Y. Weng, N. Shanmugam, R. Natarajan, S. Rahbar

Erschienen in: Diabetologia | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

Previous studies have shown that LR-90, a new inhibitor of AGE formation, prevented the development of experimental type 1 diabetic nephropathy. In this study, we examined the effects of LR-90 in the Zucker diabetic fatty (ZDF) rat, a model of type 2 diabetes and metabolic syndrome, and investigated the mechanisms by which it may protect against renal injury.

Methods

Male ZDF rats were treated without or with LR-90 from age 13 to 40 weeks. Metabolic and kidney functions and renal histology were evaluated. AGE accumulation and the production of the receptor for AGE (AGER) were measured. Profibrotic growth factors, extracellular matrix proteins and intracellular signalling pathways associated with glomerular and tubular damage were also analysed.

Results

LR-90 dramatically reduced plasma lipids in ZDF rats, with only modest effects on hyperglycaemia. Renal AGE, AGER and lipid peroxidation were all attenuated by LR-90. LR-90 significantly retarded the increase in albuminuria and proteinuria. This was associated with reduction in glomerulosclerosis and tubulointerstitial fibrosis, concomitant with marked inhibition of renal overproduction of TGF-β1, connective tissue growth factor, fibronectin and collagen IV. Additionally, LR-90 downregulated the activation of key mitogen-activated protein kinases (MAPKs) and nuclear factor kappa B (NF-κB) in the renal cortex.

Conclusions/interpretation

These results support our earlier studies on the renoprotective effects of LR-90 on type 1 diabetic nephropathy and provide further evidence that LR-90, an AGE inhibitor with pleiotrophic effects, may also be beneficial for the prevention of type 2 diabetic nephropathy, where multiple risk factors, such as hyperglycaemia, dyslipidaemia, obesity, insulin resistance and hypertension, contribute to renal injury.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Friedman EA, Friedman AL (2007) Is there really good news about pandemic diabetic nephropathy? Nephrol Dial Transplant 22:681–683PubMedCrossRef Friedman EA, Friedman AL (2007) Is there really good news about pandemic diabetic nephropathy? Nephrol Dial Transplant 22:681–683PubMedCrossRef
2.
Zurück zum Zitat Rossing P (2006) Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 6:479–483PubMedCrossRef Rossing P (2006) Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history. Curr Diab Rep 6:479–483PubMedCrossRef
3.
Zurück zum Zitat Lehmann R, Schleicher ED, Lehmann R, Schleicher ED (2000) Molecular mechanism of diabetic nephropathy. Clin Chim Acta 297:135–144PubMedCrossRef Lehmann R, Schleicher ED, Lehmann R, Schleicher ED (2000) Molecular mechanism of diabetic nephropathy. Clin Chim Acta 297:135–144PubMedCrossRef
4.
Zurück zum Zitat Raptis AE, Viberti G (2001) Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 109(Suppl 2):S424–S437PubMedCrossRef Raptis AE, Viberti G (2001) Pathogenesis of diabetic nephropathy. Exp Clin Endocrinol Diabetes 109(Suppl 2):S424–S437PubMedCrossRef
5.
Zurück zum Zitat Thomas MC, Forbes JM, Cooper ME (2005) Advanced glycation end products and diabetic nephropathy. Am J Ther 12:562–572PubMedCrossRef Thomas MC, Forbes JM, Cooper ME (2005) Advanced glycation end products and diabetic nephropathy. Am J Ther 12:562–572PubMedCrossRef
6.
Zurück zum Zitat Bohlender JM, Franke S, Stein G, Wolf G (2005) Advanced glycation end products and the kidney. Am J Physiol 289:F645–F659 Bohlender JM, Franke S, Stein G, Wolf G (2005) Advanced glycation end products and the kidney. Am J Physiol 289:F645–F659
7.
Zurück zum Zitat Horie K, Miyata T, Maeda K et al (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100:2995–3004PubMedCrossRef Horie K, Miyata T, Maeda K et al (1997) Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. J Clin Invest 100:2995–3004PubMedCrossRef
8.
Zurück zum Zitat Tanji N, Markowitz GS, Fu C et al (2000) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11:1656–1666PubMed Tanji N, Markowitz GS, Fu C et al (2000) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 11:1656–1666PubMed
9.
Zurück zum Zitat Jensen LJ, Ostergaard J, Flyvbjerg A (2005) AGE-RAGE and AGE cross-link interaction: important players in the pathogenesis of diabetic kidney disease. Horm Metab Res 37(Suppl 1):26–34PubMedCrossRef Jensen LJ, Ostergaard J, Flyvbjerg A (2005) AGE-RAGE and AGE cross-link interaction: important players in the pathogenesis of diabetic kidney disease. Horm Metab Res 37(Suppl 1):26–34PubMedCrossRef
10.
Zurück zum Zitat Tan AL, Forbes JM, Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27:130–143PubMedCrossRef Tan AL, Forbes JM, Cooper ME (2007) AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol 27:130–143PubMedCrossRef
11.
Zurück zum Zitat Peterson RG Shaw WN, Neel MA et al (1990) Zucker diabetic fatty as a model for non-insulin dependent diabetes mellitus. ILAR News 32:16–19 Peterson RG Shaw WN, Neel MA et al (1990) Zucker diabetic fatty as a model for non-insulin dependent diabetes mellitus. ILAR News 32:16–19
12.
Zurück zum Zitat Kasiske BL, O’Donnell MP, Keane WF (1992) The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19(Suppl 1):I110–I115PubMed Kasiske BL, O’Donnell MP, Keane WF (1992) The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19(Suppl 1):I110–I115PubMed
13.
Zurück zum Zitat Vora JP, Zimsen SM, Houghton DC, Anderson S (1996) Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol 7:113–117PubMed Vora JP, Zimsen SM, Houghton DC, Anderson S (1996) Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes. J Am Soc Nephrol 7:113–117PubMed
14.
Zurück zum Zitat Coimbra TM, Janssen U, Grone HJ et al (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 571:167–182CrossRef Coimbra TM, Janssen U, Grone HJ et al (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 571:167–182CrossRef
15.
Zurück zum Zitat Chander PN, Gealekman O, Brodsky SV et al (2004) Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 15:2391–2403PubMedCrossRef Chander PN, Gealekman O, Brodsky SV et al (2004) Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen. J Am Soc Nephrol 15:2391–2403PubMedCrossRef
16.
Zurück zum Zitat McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH (2000) Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58:2341–2350PubMedCrossRef McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH (2000) Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58:2341–2350PubMedCrossRef
17.
Zurück zum Zitat Baylis C, Atzpodien EA, Freshour G, Engels K (2003) Peroxisome proliferator-activated receptor γ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307:854–860PubMedCrossRef Baylis C, Atzpodien EA, Freshour G, Engels K (2003) Peroxisome proliferator-activated receptor γ agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307:854–860PubMedCrossRef
18.
Zurück zum Zitat Mizuno M, Sada T, Kato M, Koike H (2002) Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 25:271–278PubMedCrossRef Mizuno M, Sada T, Kato M, Koike H (2002) Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 25:271–278PubMedCrossRef
19.
Zurück zum Zitat Wihler C, Schäfer S, Schmid K et al (2005) Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia 48:1645–1653PubMedCrossRef Wihler C, Schäfer S, Schmid K et al (2005) Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition. Diabetologia 48:1645–1653PubMedCrossRef
20.
Zurück zum Zitat Schäfer S, Linz W, Vollert H et al (2004) The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy. Diabetologia 47:98–103PubMedCrossRef Schäfer S, Linz W, Vollert H et al (2004) The vasopeptidase inhibitor AVE7688 ameliorates type 2 diabetic nephropathy. Diabetologia 47:98–103PubMedCrossRef
21.
Zurück zum Zitat Schrijvers BF, Flyvbjerg A, Tilton RG et al (2006) A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 21:324–329PubMedCrossRef Schrijvers BF, Flyvbjerg A, Tilton RG et al (2006) A neutralizing VEGF antibody prevents glomerular hypertrophy in a model of obese type 2 diabetes, the Zucker diabetic fatty rat. Nephrol Dial Transplant 21:324–329PubMedCrossRef
22.
Zurück zum Zitat Rahbar S, Figarola JL (2003) Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 419:63–79PubMedCrossRef Rahbar S, Figarola JL (2003) Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 419:63–79PubMedCrossRef
23.
Zurück zum Zitat Rahbar S (2007) Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys 48:147–157PubMedCrossRef Rahbar S (2007) Novel inhibitors of glycation and AGE formation. Cell Biochem Biophys 48:147–157PubMedCrossRef
24.
Zurück zum Zitat Figarola JL, Scott S, Loera S et al (2003) LR-90, a novel advanced glycation endproduct inhibitor, prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46:1140–1152PubMedCrossRef Figarola JL, Scott S, Loera S et al (2003) LR-90, a novel advanced glycation endproduct inhibitor, prevents progression of diabetic nephropathy in streptozotocin-diabetic rats. Diabetologia 46:1140–1152PubMedCrossRef
25.
Zurück zum Zitat Figarola JL, Rahbar S, Scott S et al (2005) Prevention of early renal disease, dyslipidemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes Metab Res Rev 21:533–544PubMedCrossRef Figarola JL, Rahbar S, Scott S et al (2005) Prevention of early renal disease, dyslipidemia and lipid peroxidation in STZ-diabetic rats by LR-9 and LR-74, novel AGE inhibitors. Diabetes Metab Res Rev 21:533–544PubMedCrossRef
26.
Zurück zum Zitat Figarola JL, Shanmugam N, Natarajan R, Rahbar S (2007) Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 56:647–655PubMedCrossRef Figarola JL, Shanmugam N, Natarajan R, Rahbar S (2007) Anti-inflammatory effects of the advanced glycation end product inhibitor LR-90 in human monocytes. Diabetes 56:647–655PubMedCrossRef
27.
Zurück zum Zitat Wilkinson-Berka JL, Kelly DJ, Koerner SM et al (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) rat. Diabetes 51:3283–3289PubMedCrossRef Wilkinson-Berka JL, Kelly DJ, Koerner SM et al (2002) ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2) rat. Diabetes 51:3283–3289PubMedCrossRef
28.
Zurück zum Zitat Ohga S, Shikata K, Yozai K et al (2006) Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am J Physiol 292:F1141–F1150CrossRef Ohga S, Shikata K, Yozai K et al (2006) Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-κB activation. Am J Physiol 292:F1141–F1150CrossRef
29.
Zurück zum Zitat Reckelhoff JF, Kanji V, Racusen LC et al (1998) Vitamin E ameliorates enhanced renal lipid peroxidation and accumulation of F2-isoprostanes in aging kidneys. Am J Physiol 274:R767–R774PubMed Reckelhoff JF, Kanji V, Racusen LC et al (1998) Vitamin E ameliorates enhanced renal lipid peroxidation and accumulation of F2-isoprostanes in aging kidneys. Am J Physiol 274:R767–R774PubMed
30.
Zurück zum Zitat Chuang L, Guh J (2001) Extracellular signals and intracellular pathways in diabetic nephropathy. Nephrology 6:165–172CrossRef Chuang L, Guh J (2001) Extracellular signals and intracellular pathways in diabetic nephropathy. Nephrology 6:165–172CrossRef
31.
Zurück zum Zitat Thomas MC, Atkins RC (2006) Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 66:2213–2234PubMedCrossRef Thomas MC, Atkins RC (2006) Blood pressure lowering for the prevention and treatment of diabetic kidney disease. Drugs 66:2213–2234PubMedCrossRef
32.
Zurück zum Zitat Song JH, Cha SH, Hong SB, Kim DH (2006) Dual blockade of the rennin–angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens Suppl 24:S101–S106PubMedCrossRef Song JH, Cha SH, Hong SB, Kim DH (2006) Dual blockade of the rennin–angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease. J Hypertens Suppl 24:S101–S106PubMedCrossRef
33.
Zurück zum Zitat Davis BJ, Forbes JM, Thomas MC et al (2004) Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47:89–97PubMedCrossRef Davis BJ, Forbes JM, Thomas MC et al (2004) Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 47:89–97PubMedCrossRef
34.
Zurück zum Zitat Wu YG, Lin H, Qian H et al (2006) Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflamm Res 55:192–199PubMedCrossRef Wu YG, Lin H, Qian H et al (2006) Renoprotective effects of combination of angiotensin converting enzyme inhibitor with mycophenolate mofetil in diabetic rats. Inflamm Res 55:192–199PubMedCrossRef
35.
Zurück zum Zitat Forbes JM, Fukami K, Cooper ME (2007) Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 115:69–84PubMedCrossRef Forbes JM, Fukami K, Cooper ME (2007) Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 115:69–84PubMedCrossRef
36.
Zurück zum Zitat Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14:1358–1373PubMedCrossRef Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14:1358–1373PubMedCrossRef
37.
Zurück zum Zitat Reeves WB, Andreoli TE (2000) Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci U S A 97:7667–7669PubMedCrossRef Reeves WB, Andreoli TE (2000) Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci U S A 97:7667–7669PubMedCrossRef
38.
Zurück zum Zitat Wahab NA, Yevdokimova N, Weston BS et al (2001) Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 359:77–87PubMedCrossRef Wahab NA, Yevdokimova N, Weston BS et al (2001) Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem J 359:77–87PubMedCrossRef
39.
Zurück zum Zitat Pugliese G, Pricci F, Romeo G et al (1997) Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 46:1881–1887PubMedCrossRef Pugliese G, Pricci F, Romeo G et al (1997) Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism. Diabetes 46:1881–1887PubMedCrossRef
40.
Zurück zum Zitat Zhou G, Li C, Cai L (2004) Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol 165:2033–2043PubMed Zhou G, Li C, Cai L (2004) Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor β-independent pathway. Am J Pathol 165:2033–2043PubMed
41.
Zurück zum Zitat Crean JK, Finlay D, Murphy M et al (2002) The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J Biol Chem Nov 277:44187–44194CrossRef Crean JK, Finlay D, Murphy M et al (2002) The role of p42/44 MAPK and protein kinase B in connective tissue growth factor induced extracellular matrix protein production, cell migration, and actin cytoskeletal rearrangement in human mesangial cells. J Biol Chem Nov 277:44187–44194CrossRef
42.
Zurück zum Zitat Fujita H, Omori S, Ishikura K et al (2004) ERK and p38 mediate high-glucose-induced hypertrophy and TGF-β expression in renal tubular cells. Am J Physiol 286:F120–F126 Fujita H, Omori S, Ishikura K et al (2004) ERK and p38 mediate high-glucose-induced hypertrophy and TGF-β expression in renal tubular cells. Am J Physiol 286:F120–F126
43.
Zurück zum Zitat Zill H, Bek S, Hofmann T et al (2003) RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun 300:311–315PubMedCrossRef Zill H, Bek S, Hofmann T et al (2003) RAGE-mediated MAPK activation by food-derived AGE and non-AGE products. Biochem Biophys Res Commun 300:311–315PubMedCrossRef
44.
Zurück zum Zitat Yeh CH, Sturgis L, Haidacher J et al (2001) Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50:1495–1504PubMedCrossRef Yeh CH, Sturgis L, Haidacher J et al (2001) Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 50:1495–1504PubMedCrossRef
45.
Zurück zum Zitat Lee HB, Yu MR, Yang Y, Jiang Z, Ha H (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14(Suppl 3):S241–S245PubMedCrossRef Lee HB, Yu MR, Yang Y, Jiang Z, Ha H (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14(Suppl 3):S241–S245PubMedCrossRef
46.
Zurück zum Zitat Suzaki Y, Ozawa Y, Kobori H (2006) Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci 3:40–46PubMed Suzaki Y, Ozawa Y, Kobori H (2006) Intrarenal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fatty rats. Int J Biol Sci 3:40–46PubMed
47.
Zurück zum Zitat Chang JM, Kuo MC, Kuo HT et al (2005) Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. J Lab Clin Med 146:210–215PubMedCrossRef Chang JM, Kuo MC, Kuo HT et al (2005) Increased glomerular and extracellular malondialdehyde levels in patients and rats with diabetic nephropathy. J Lab Clin Med 146:210–215PubMedCrossRef
48.
Zurück zum Zitat Abrass CK (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46–53PubMedCrossRef Abrass CK (2004) Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 24:46–53PubMedCrossRef
49.
50.
Zurück zum Zitat Lassila M, Seah KK, Allen TJ et al (2004) Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15:2125–2138PubMedCrossRef Lassila M, Seah KK, Allen TJ et al (2004) Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 15:2125–2138PubMedCrossRef
51.
Zurück zum Zitat Dominguez JH, Tang N, Xu W et al (2000) Studies of renal injury III: lipid-induced nephropathy in type II diabetes. Kidney Int 57:92–104PubMedCrossRef Dominguez JH, Tang N, Xu W et al (2000) Studies of renal injury III: lipid-induced nephropathy in type II diabetes. Kidney Int 57:92–104PubMedCrossRef
Metadaten
Titel
LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat
verfasst von
J. L. Figarola
S. Loera
Y. Weng
N. Shanmugam
R. Natarajan
S. Rahbar
Publikationsdatum
01.05.2008
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 5/2008
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-0935-x

Weitere Artikel der Ausgabe 5/2008

Diabetologia 5/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.